RVMD - Revolution Medicines - Stock & Dividends

Revolution Medicines Inc. is a clinical-stage precision oncology company that focuses on developing innovative targeted therapies for RAS-addicted cancers, a type of cancer that is driven by mutations in the RAS gene.

The company's research and development pipeline is built around two main categories of therapies: RAS(ON) inhibitors and RAS companion inhibitors. RAS(ON) inhibitors are designed to target specific mutations in the RAS gene, with the goal of treating cancer as a monotherapy or in combination with other RAS(ON) inhibitors or therapeutic agents. The company has several RAS(ON) inhibitors in its pipeline, including RMC-6236, RMC-6291, and RMC-9805, which are currently in phase 1 clinical trials.

In addition to RAS(ON) inhibitors, Revolution Medicines is also developing RAS companion inhibitors, which are designed to be used in combination with other therapies to enhance their effectiveness. The company's RAS companion inhibitors, such as RMC-4630 and RMC-5552, are currently in phase 2 and phase 1 clinical trials, respectively.

Revolution Medicines' pipeline also includes several development candidates, including RMC-5127, RMC-0708, and RMC-8839, which are focused on targeting specific RAS mutations, such as G12V, Q61H, and G13C. The company is also exploring programs focused on other RAS mutations, including G12R.

Founded in 2014, Revolution Medicines is headquartered in Redwood City, California, and is committed to advancing its pipeline of precision oncology therapies to improve treatment options for patients with RAS-addicted cancers. For more information, visit the company's website at https://www.revmed.com.